RET and thyroid gland carcinoma: Despite achievement in CCDC6-RET-rearranged thyroid cancer cells, they found that exposure to either cabozantinib (a non-selective RET-TKIs) or BLU6864 (a selective RET-TKIs) is associated with rapid inhibition of ERK1/2 signaling.